Cerus (CERS) Stock Rating Upgraded by ValuEngine

ValuEngine upgraded shares of Cerus (NASDAQ:CERS) from a strong sell rating to a sell rating in a report published on Thursday.

CERS has been the subject of a number of other reports. Robert W. Baird reaffirmed a buy rating and set a $5.00 price target on shares of Cerus in a research note on Friday, December 1st. Zacks Investment Research cut shares of Cerus from a hold rating to a sell rating in a research note on Tuesday, October 3rd. BidaskClub cut shares of Cerus from a hold rating to a sell rating in a research note on Tuesday, December 12th. Cowen set a $6.00 price target on shares of Cerus and gave the stock a buy rating in a research note on Thursday, October 5th. Finally, BTIG Research reaffirmed a neutral rating on shares of Cerus in a research note on Friday, December 8th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the stock. Cerus has a consensus rating of Hold and an average price target of $5.83.

Cerus (CERS) traded up $0.34 during mid-day trading on Thursday, hitting $4.18. 1,881,329 shares of the company were exchanged, compared to its average volume of 500,400. Cerus has a 52-week low of $1.93 and a 52-week high of $4.70. The company has a debt-to-equity ratio of 0.80, a quick ratio of 3.11 and a current ratio of 3.71. The stock has a market cap of $480.30, a PE ratio of -7.08 and a beta of 1.93.

Cerus (NASDAQ:CERS) last released its quarterly earnings results on Thursday, November 2nd. The biotechnology company reported ($0.12) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.03. Cerus had a negative net margin of 159.35% and a negative return on equity of 142.18%. The firm had revenue of $10.80 million during the quarter, compared to analysts’ expectations of $11.95 million. During the same period in the previous year, the company earned ($0.14) EPS. The firm’s revenue for the quarter was up 5.9% compared to the same quarter last year. equities research analysts predict that Cerus will post -0.57 earnings per share for the current fiscal year.

A number of institutional investors have recently added to or reduced their stakes in CERS. Marshall Wace North America L.P. purchased a new stake in Cerus in the 2nd quarter valued at about $316,000. Stephens Inc. AR boosted its position in Cerus by 1.4% in the 2nd quarter. Stephens Inc. AR now owns 963,702 shares of the biotechnology company’s stock valued at $2,419,000 after buying an additional 12,973 shares during the period. Teachers Advisors LLC boosted its position in Cerus by 9.7% in the 2nd quarter. Teachers Advisors LLC now owns 260,081 shares of the biotechnology company’s stock valued at $653,000 after buying an additional 22,896 shares during the period. Elk Creek Partners LLC boosted its position in Cerus by 32.3% in the 2nd quarter. Elk Creek Partners LLC now owns 5,739,285 shares of the biotechnology company’s stock valued at $14,406,000 after buying an additional 1,402,106 shares during the period. Finally, UBS Asset Management Americas Inc. boosted its position in Cerus by 59.3% in the 2nd quarter. UBS Asset Management Americas Inc. now owns 48,377 shares of the biotechnology company’s stock valued at $121,000 after buying an additional 18,000 shares during the period. 55.72% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This report was published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this report on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The original version of this report can be read at https://www.com-unik.info/2018/01/08/cerus-cers-stock-rating-upgraded-by-valuengine.html.

About Cerus

Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Cerus (NASDAQ:CERS)

What are top analysts saying about Cerus? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Cerus and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit